A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Inclusion Criteria:

Confirmed no evidence of cancer on computed tomography (CT) scan within 6 months prior to starting treatment
Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
Patients must have platelets >= 100 x 10^9/L

Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry

Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
PATIENTS AT HIGH-RISK FOR LUNG CANCER COHORT ONLY (COHORT A)

Must have documented at least one risk factor for lung cancer which includes:

Moderate to severe chronic obstructive pulmonary disease (COPD) defined as FEV1/FVC ratio <=75%
Positive family history of lung cancer defined as a first degree relative
Low body mass index (BMI)
History of pneumonia within the last 5 years prior to enrollment
Occupational exposure such as asbestos, radon and any other that investigator would deem high risk
Must have quit smoking =< 15 years ago or be a current smoker
Must have at least 30 pack year smoking history
Must have documented pulmonary function test within the last 3 years prior to enrollment. If a patient cannot tolerate a pulmonary function test, an incentive spirometry will be acceptable in place of a pulmonary function test
LUNG CANCER SURVIVOR COHORT ONLY (COHORT B)
1. If patient received surgery or any adjuvant therapy for initial diagnosis of lung cancer, it must have been completed at least 3 months prior to enrollment. Prior surgery or any therapy is not required for eligibility
Confirmed non-small cell lung cancer (NSCLC) stage IA through 3A at initial diagnosis

Exclusion Criteria:

Clinically inappropriate to have a bronchoscopy procedure
Known uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, history of clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant or nursing female participants
Unwilling or unable to follow protocol requirements
Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug
Received an investigational agent within 30 days prior to enrollment
Has known immunosuppressive disease (e.g. human immunodeficiency virus [HIV], acquired immunodeficiency syndrome [AIDS] or other immune depressing disease). Testing is not mandatory
Patient has known hypersensitivity to the components of the study drugs or any analogs
History of autoimmune disorder, with exception of patients with vitiligo or endocrine-related autoimmune conditions receiving appropriate hormonal supplementation who are eligible. Systemic use of immunosuppressant drugs such as steroids (except as hormone replacement therapy or short-course supportive medication such as chemotherapy or drug allergy, etc.), azathioprine, tacrolimus, cyclosporine, etc. within 4 weeks before recruitment

The following special populations are excluded from this study:

Cognitively impaired adults/adults with impaired decision-making capacity
Individuals who are not yet adults (infants, children, teenagers)
Prisoners
Pregnant women